Author

Q. Yuan

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Schisandrin B alleviates hepatic damage and hepatic lipid metabolic dysregulation induced by microcystin-LR.

Microcystin-LR (MC-LR) is a common biological pollutant found in aquatic environments; it induces severe liver injury, inflammation and lipid metabolic disorders. The potential mechanisms underlying MC-LR pathogenesis is still unclear, and effective therapeutic drugs remain to be explored through in-depth research. Thi...

Xia-Xia Yuan, Sheng-Nan Lv, Ying-Tong Li et al. · Ecotoxicology and Environmen... · 0 citations

Sep 2026

POLE2 of tumor cells promotes OPN secretion based on PCLAF to drive M2 macrophage polarization in clear cell renal cell carcinoma.

A comprehensive NFATc2/POLE2/PCLAF signaling axis that promotes ccRCC progression via OPN-mediated M2 macrophage polarization, providing a solid rationale and potential therapeutic targets for developing novel immunocombination therapies is unveiled.

An-Rui Li, Jing-Wen Xu, Zhi-Hang Wu et al. · Cancer Gene Therapy · 0 citations

Open access Aug 2026

TUDCA was identified as a potential therapeutic drug for nonalcoholic steatohepatitis complicated with hypercholesterolemia targeting ADRA2C by integrated bioinformatics and experimental verification

Nonalcoholic steatohepatitis (NASH) is a type of liver disease in which fat accumulates in the liver with inflammation. Hypercholesterolemia is a common autosomal dominant inherited metabolic disease. Previous studies have suggested a potential association between NASH and hypercholesterolemia, but the pathophysiolog...

Hongfeng Liu, Yuxiao Fan, Zhanpeng Sun et al. · Biology Direct · 0 citations